Question 1
What is the cell concentration in solution three, when combining solution one and solution two?
Correct Answer:
3.4 x 106 cells/ml
Explanation:
To determine the cell concentration in solution three, when combining solutions one and two, it is necessary to perform a calculation that considers the initial concentrations of both solutions along with their respective volumes. The overall concentration in the final solution can be calculated using the formula for mixing two solutions, which involves summing the total number of cells from both solutions and dividing that sum by the total volume of the resulting mixture. If solution one, for example, has a concentration of a certain number of cells per milliliter and solution two has a different concentration, when they are combined, the total number of cells will be the sum of the cells in both solutions. The final volume will also be the total volume of both solutions combined. After performing these calculations accurately, if the result corresponds to 3.4 x 10^6 cells/ml, this confirms that the concentration of cells in solution three is based on correct arithmetic that reflects the distribution and concentration of cells from both incorporated solutions. Therefore, choosing this concentration indicates that the calculation of combined cell numbers and the total resultant volume was executed correctly, leading to the valid conclusion about the concentration of the third solution.
Question 2
How many possible reading frames exist for a eukaryotic DNA sequence of length 200bp that contains an exon of 180bp?
Correct Answer:
6
Explanation:
The correct answer is based on the principle of how reading frames work in nucleic acid sequences. In any given segment of DNA, particularly within a coding region, there are multiple ways to interpret the sequence in terms of potential protein-coding sequences, which is what reading frames represent. For a eukaryotic DNA sequence, the coding region (exon) is read in triplets called codons, and since DNA is double-stranded, each strand can serve as a template for translation. In a single-stranded context, the sequence can be read in three possible frames starting from one of the three nucleotides. Additionally, because a DNA sequence is bi-directional (it can be read from both strands), you can also derive three reading frames from the complementary strand. This results in a total of six reading frames: three from the original strand and three from the reverse complementary strand. In this scenario, you have a 200bp DNA sequence containing an exon of 180bp. While the length of the exon is significant, it does not change the calculation of how many reading frames are created from the entire sequence. Thus, the total possible reading frames for this exon-containing sequence is six, confirming that the understanding of reading frames in
Question 3
Which of the following statements is TRUE regarding chronic rejection?
Correct Answer:
It can involve both antibodies and T cells
Explanation:
Chronic rejection is a complex immunological process that occurs over an extended period, typically months to years after transplantation, rather than immediately after the procedure. The key aspect of chronic rejection is that it is characterized by both the involvement of antibodies and T cells, leading to progressive damage to the transplanted tissue. While T cells play a significant role, chronic rejection is particularly noted for the involvement of antibodies that target the graft. This antibody-mediated component often contributes to the gradual deterioration of the graft function. Hence, stating that chronic rejection can involve both antibodies and T cells accurately highlights the multi-faceted nature of the immune response during this phase of rejection. This contrasts with other statements that suggest conditions and mechanisms not typically associated with chronic rejection. For example, chronic rejection does not occur within days of transplantation, as that's more characteristic of acute rejection, and it is not limited to kidney transplants, as chronic rejection can affect any type of transplanted organ.
Question 4
Which sample is preferred for molecular testing of class II HLA antigens?
Correct Answer:
2ml peripheral blood in EDTA
Explanation:
The preferred sample for molecular testing of class II HLA antigens is peripheral blood in EDTA. This choice is favored primarily because EDTA acts as an anticoagulant, preventing blood from clotting and thus preserving the integrity of the leukocytes in the sample. When testing for HLA class II antigens, functional and genomic analysis requires intact lymphocytes. Peripheral blood, when collected with EDTA, maintains the cells in a state suitable for molecular assays, such as PCR or sequencing. The leukocytes can readily be isolated from the whole blood for further genetic analysis. Moreover, using peripheral blood minimizes the need for complex processing or manipulation that might compromise cell viability or DNA integrity. The use of EDTA ensures that the blood remains in a liquid state, which allows for optimal cellular handling. Other methods of sample preparation, like Ficoll separation or transformed B cell lines, may introduce variables that are less desirable for molecular testing or may not represent the natural population of HLA class II antigens in an individual's immune system as effectively.
Question 5
According to ASHI standards (2005), which information MUST be included on an HLA typing report?
Correct Answer:
The laboratory's address
Explanation:
The inclusion of the laboratory's address on an HLA typing report is essential for several reasons. It provides a clear point of contact for the results and verifies the legitimacy of the report. This transparency ensures that healthcare providers and patients can confirm the origin of the results, allowing for proper follow-up or consultation if necessary. The laboratory's address also contributes to the traceability of the report, which can be critical in the context of clinical care, especially when dealing with transplant patients who require precise HLA matching. While the other options may contain relevant information, they do not carry the same requirement as stipulated by ASHI standards. The names of all directors and supervisors, while important for quality assurance, do not need to be included for the report's validity. The IMGT library used for allele assignments is valuable for technical reproducibility, but not mandated by these standards. Lastly, a patient's diagnosed disease state can be pertinent for clinical context but is not a mandatory component for reporting HLA typing results as per ASHI.
Question 1
Exam overview

About this Exam

The Certified Histocompatibility Specialist (CHS) designation represents the highest level of non-doctoral certification in the field of histocompatibility and immunogenetics.

This advanced certification, administered by the American College of Histocompatibility and Immunogenetics (ACHI), is designed for experienced laboratory professionals who have demonstrated significant expertise and supervisory capability in a histocompatibility and immunogenetics (H&I) laboratory.

A CHS is a critical team member in the context of organ and tissue transplantation. They perform and oversee complex testing to match donors and recipients, analyze human leukocyte antigen (HLA) patterns, and assess immunological risk factors. This role is crucial for ensuring the safety and long-term success of transplant procedures and for supporting the diagnosis of immunologically-related diseases.

The CHS practice test is an invaluable tool for candidates preparing for this challenging exam, offering a focused method to assess knowledge, identify gaps, and simulate the pressure of the final, decisive evaluation.

More details

Additional Information

What the Course Entails and Exam Details

Preparing for the Certified Histocompatibility Specialist examination requires a deep and comprehensive understanding of multiple facets of immunology and advanced laboratory technologies.

The official ACHI exam content outline details the precise distribution of topics. Candidates can expect to encounter questions covering the following core areas:

  • Immunology: Fundamental principles, including the structure and function of the human immune system, antigen processing, and the biology of T and B cells.
  • HLA Genetics: The organization, inheritance, and nomenclature of the HLA gene complex, including its role in antigen presentation and disease association.
  • Histocompatibility Testing Methods: Detailed knowledge of established and evolving laboratory techniques. This includes serological methods (microlymphocytotoxicity), flow cytometry, and advanced molecular technologies (SSP, SSO, SBT, and Next-Generation Sequencing - NGS).
  • Clinical Applications: The practical application of H&I testing in different clinical settings, such as solid organ transplantation (renal, heart, lung, liver), hematopoietic progenitor cell transplantation (HPCT), and disease diagnosis.
  • Antibody Analysis: Detection and characterization of anti-HLA antibodies, including crossmatching techniques and solid-phase assays (e.g., Luminex), and their impact on patient outcomes.
  • Quality Management and Regulatory Compliance: Comprehensive understanding of lab operations, quality assurance, control procedures, safety regulations, and compliance with standards from organizations like CLIA, CAP, and ASHI.
  • Calculations and Problem-Solving: Applying statistical methods and genetic principles to solve clinical problems and interpret testing data.

 

What to Expect in the Final Exam

The actual Certified Histocompatibility Specialist examination is a comprehensive, proctored test administered in a computer-based format.

Here is what candidates should anticipate on exam day:

  • Exam Format: The exam exclusively uses multiple-choice questions. For the CHS level, the test typically contains 150 scored questions, covering the full scope of the detailed content outline.
  • Time Limit: The examination is conducted within a specified, structured time window, usually lasting several hours. This includes time for a brief tutorial and an introduction to the computer-based system.
  • Passing Score: ACHI does not publish a single, static raw passing number. Instead, they use a sophisticated standard-setting methodology that results in a scaled score. This ensures fairness and consistent passing standards across different versions of the exam.
  • Exam Integrity: The exam is strictly proctored to ensure validity. Candidates must present valid identification, and no personal materials, notes, or unauthorized electronic devices are allowed into the testing area.

 

How to Study and Exam Centers

Preparation is paramount for the CHS exam. To achieve a passing score, you must develop a structured and comprehensive study plan.

Here are actionable strategies for success:

  • Master the ACHI Candidate Handbook: Your first step must be to thoroughly review the official ACHI Examination Candidate Handbook. This document contains the essential content outline, eligibility requirements, and vital logistical details.
  • Utilize a Variety of Study Materials: Do not rely on a single resource. Combine the content outline with leading textbooks on immunology and transplantation, online educational tools, and peer-reviewed journals to broaden your understanding of current practices and emerging technologies.
  • Take Advantage of ASHI University: The American Society for Histocompatibility and Immunogenetics (ASHI) offers an extensive educational platform called ASHI University (ASHI U). This resource includes modules, webinars, and other learning materials specifically curated for H&I professionals.
  • Engage in Practice Tests: Regularly use a dedicated [Certified Histocompatibility Specialist Practice Test]. These tools are critical for familiarizing yourself with the multiple-choice format, practicing under timed conditions, and developing the critical-thinking and application skills needed to succeed.
  • Join Study Groups: Collaborating with colleagues who are also preparing for the exam can provide support, multiple perspectives on complex topics, and a shared motivation.

 

How to Take the Exam

The ACHI CHS exam is administered globally in partnership with standard professional testing organizations.

  • Physical Testing Centers: Candidates can take the exam at an authorized, secure Pearson VUE professional test center. These locations provide a standardized and controlled environment.
  • Online Proctoring: For added convenience, ACHI also offers the option to take the exam via OnVUE online proctoring. This allows you to complete the test from a secure, private location using your own computer, provided you meet the technical and environmental requirements.
  • Registration Process: Candidates must first submit a comprehensive application to ACHI to verify their professional eligibility. Once approved, they will receive an Authorization to Test (ATT) email with instructions on how to schedule their preferred exam date and location.

 

Job Opportunities from the Course

Earning the Certified Histocompatibility Specialist credential validates your high-level expertise and significantly enhances your career trajectory within the transplantation community.

This certification unlocks numerous pathways and supervisory roles. Here is a list of job titles and career paths this achievement supports:

  • Histocompatibility Specialist
  • HLA Laboratory Technologist / Specialist (with supervisory responsibilities)
  • Histocompatibility Laboratory Supervisor
  • Transplant Coordinator (clinical or laboratory-focused)
  • Quality Assurance Specialist / Manager in H&I
  • Transplantation Immunology Research Specialist
  • HLA Informatics Specialist
Quiz information

Frequently Asked Questions

The complete question count is available after full access is unlocked.
No fixed duration is currently configured for this quiz.
Question explanations are included where they are available in the quiz content, helping you review the reasoning after answering.
Yes. You can retake the practice test again as you continue studying during your available access period.
After your access is confirmed, you can continue into the complete practice exam from this quiz flow.
Unless explicitly stated otherwise, this page provides independent practice material for study and exam preparation and is not the official examination itself.
Keep studying

Related Questions